On an earnings call dominated by discussion about the impact of biosimilar competition to its top-seller Remicade (infliximab), Johnson & Johnson pointed to a growing oncology business and an abundant late-stage pipeline on Oct. 18, saying it will file 10 new molecular entities for approval during 2015-2019 that have blockbuster sales potential.
In cancer, Worldwide Chairman-Pharmaceuticals Joaquin Duato cited continued sales growth for Imbruvica (ibrutinib) and a promising launch for Darzalex (daratumumab)...








